Structure Therapeutics
Live price unavailable. Yahoo unofficial endpoint may be throttling or the ticker may be misconfigured.
loading 1-year chart…
1-year close · Yahoo Finance · daily interval
What they do in peptide space
Structure Therapeutics is developing GSBR-209 (formerly aleniglipron, GSBR-209), an oral small-molecule GLP-1 receptor agonist designed using the company's structure-based drug discovery platform. The compound is in Phase 2 development for obesity and type 2 diabetes.
The pitch: structure-based discovery should produce more selective receptor binding than the amino-acid-engineering approach used for peptide GLP-1s, potentially yielding better tolerability and lower nausea at therapeutic doses. Phase 2 data in 2024-2025 has been moderately encouraging on weight loss but the GI tolerability differentiation hasn't yet stood out from peer compounds.
The company is one of several oral-GLP-1 challengers (alongside Pfizer's danuglipron and Lilly's orforglipron) competing for what could be a substantially larger TAM than the injectable market — but we are years from knowing which of these molecules, if any, become clinical winners.
Recent mentions
Coming soon — no editorial coverage or FDA alert mentioning Structure Therapeutics in our index yet. Items will surface here as the news / FDA cron pipelines ingest them.